GRI Bio GRI
NASDAQ GRI
$1.65 -0.02 (-1.20%)
At close: Aug 21, 2026 · 4:00 PM EDT

GRI Bio (GRI) Non Operating Investment Income (2021 - 2022)

GRI Bio (GRI) posted quarterly Non Operating Investment Income of $2000.0 for Q3 2022, up 300.0% year-over-year from $500.0 in Q3 2021, and up 300.0% quarter-over-quarter from -$1000.0 in Q3 2021.

GRI Bio (GRI) Non Operating Investment Income (2021 - 2022) Analysis & Trends

GRI Bio's Non Operating Investment Income history runs 2 years deep, the most recent figure standing at $2000.0 for Q3 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 GRI Bio 3.01 Mn 3.01 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2022 2,000.00
Sep 30, 2022 2,000.00
Sep 30, 2021 -1,000.00
Sep 30, 2021 -1,000.00